The CCL2/CCR2 axis, which regulates monocyte recruitment and differentiation into TAMs, has been effectively targeted to disrupt TAM function and enhance tumor sensitivity to immunotherapy (16, 57). This evidence concerns the gene CCR2 and neoplasm.